

# Central retinal vein occlusion in hypertensive patient — a case report

Regina Pawlak<sup>1</sup>, Aleksandra Krasińska<sup>1</sup>, Agata Brązert<sup>2</sup>, Katarzyna Piotrowska<sup>1</sup>, Paweł Uruski<sup>1</sup>, Andrzej Tykarski<sup>1</sup>

<sup>1</sup>Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

<sup>2</sup>Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland

## Abstract

Retinal vein occlusion (RVO) is, beside diabetic retinopathy, the most common retinal vascular disease. RVO is associated with many risk factors, both systemic and ocular. Among the systemic risk factors is hypertension. A 36-year-old man came to the hospital because of impaired vision. Central retinal vein occlusion (CRVO) was diagnosed. The main reason for developing RVO was the untreated hypertension, which was diagnosed in the form of hypertensive crisis. The patient presented numerous additional CRVO risk factors that contributed to the development of the described pathology like: obesity, dyslipidaemia, hyperhomocysteinaemia, renal cancer. The authors suggested active examination for CRVO risk factors regardless of the age of patients.

**Key words:** hypertension; retinal vein occlusion; risk factor

*Arterial Hypertens.* 2019, vol. 23, no. 2, pages: 114–116  
DOI: 10.5603/AH.a2019.0010

## Introduction

Retinal vein occlusion (RVO) is, beside diabetic retinopathy, the most common retinal vascular disease [1, 2]. It is the fifth cause of blindness [3].

Two types of RVO are distinguished: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) [1, 2]. The central retinal vein occlusion is usually caused by thrombus in the vein near lamina cribrosa [1]. The alterations in the central retinal vein are secondary to sclerotic changes in nearby situated central retinal artery [1]. However, may also be combined with morphologically altered endothelium that resembles arterial endothelium [4]. The CRVO can be divided into two subtypes: non-ischaemic and ischaemic [1, 2]. Ischaemic form is often more severe [1] and less frequent [5].

The central retinal vein occlusion is manifested by a painless vision disorder. The retina's images reveal:

dilated and tortuous veins, haemorrhages, oedema and cotton wool spots [1].

There are many risk factors of RVO, among them: hypertension [1, 5, 6], dyslipidaemia [1, 6], malignancies [5], obesity [6], hyperhomocysteinaemia [1, 5], abnormal coagulation [1, 5], genetic predisposition [7].

The two main complications of RVO are macular oedema and retinal ischaemia leading to neovascularization [8].

## Case report

A 36-year-old man (BMI = 32.8 kg/m<sup>2</sup>), intellectually efficient, non-smoker, with negative family history of cardiovascular and ophthalmic diseases, was admitted to the emergency room because of blindness of the right eye for 3 days and high blood pressure.

**Address for correspondence:** Regina Pawlak MD

Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Długa 1/2, 61–848 Poznan, Poland, tel: (+48) 501 527 716, e-mail: pawlakregina@gmail.com

 Copyright © 2019 Via Medica, ISSN 2449–6170


**Table I.** Laboratory tests

Laboratory test	Test result	Norm
Total cholesterol	5.84 mmol/L	3.60–5.20 mmol/L
High-density lipoprotein	1.25 mmol/L	> 1.00 mmol/L
Low-density lipoprotein	4.62 mmol/L	< 3.60 mmol/L
Triglycerides	1.21 mmol/L	0.30–1.70 mmol/L
Homocysteine	23.3 umol/L	5.0–13.9 umol/L

He suffered from cerebral palsy from birth.

During the hospitalization additional tests showed, further abnormalities, including:

- dyslipidaemia — total cholesterol: 5.84 mmol/L, high-density lipoprotein: 1.25 mmol/L, low-density lipoprotein: 4.62 mmol/L, triglycerides: 23.3 umol/L (Tab. I);
- hyperhomocysteinaemia — 23.3 umol/L;
- mutation of the *MTHFR C677T* gene — heterozygote (genetic marker of the abnormal coagulation);
- high blood pressure:
  - 230/130 mm Hg as assessed with oBP, at admission,
  - 24-h ambulatory mean systolic and diastolic blood pressure of 152 and 89 mm Hg, respectively, mean activity time BP: 156/93 mm Hg, mean sleep time BP: 135/75 mm Hg;
- ultrasound of the abdomen: hyperechoic focal lesion (predominantly solid + little fluid) in the middle part of the right kidney;
- computing tomography (CAT scan) of the abdomen (with contrast): a heterodense cystic-solid change of 19 mm diameter in the right kidney; non-uniform contrast enhancement;
- histopathological examination of the renal tumour showed polycystic form of clear cell renal carcinoma;
- fundoscopy: right eye — papilloedema, haemorrhages and blurring of the optic disc and its margins, macular oedema, intraretinal haemorrhages and retinal oedema, dilated and tortuous retinal veins; left eye — single cotton wool spot, no other relevant changes;
- fluorescence angiography (Fig. 1):
  - right eye: extensive ecchymosis of the blood in the posterior pole and on the periphery, the disc is swollen with blurred boundaries; along the large vascular trunks, around the disc and in the macula, extensive foci of soft exudates; numerous areas of blockade of fluorescence by the blood; interrupted blood flow in many vessels; late stagnation of the dye in the vessels. The assessment of capillary circulation is

**Figure 1.** Fluorescence angiography

practically impossible, but the clinical picture speaks for high ischaemia. Central retinal vein occlusion,

- left eye — a single cotton-wool spot over the papilla; straightened blood vessels; without leakage or dye stagnation.

## Discussion

In the presented case we report on severe RVO secondary to hypertensive crisis in a patient with renal tumour.

Increased blood pressure is inherently associated with vascular damage. Mechanical stress caused by shearing forces causes endothelial dysfunction as measured by the reduced bioavailability of the nitric oxide, a potent vasodilatory factor. Concurrently, angiotensin II excess contributes to constriction of the vessels, which further confers risk of hypertension development. The examination of the retinal vessels may also show characteristic changes resulting from long-standing or uncontrolled hypertension. Narrowing of the vessels impairs capillary blood flow, which may lead to RVO, at extremes [9].

Tissue hypoxia promotes vascular endothelial growth factor (VEGF) production and release, which in turn leads to hyperperfusion. The VEGF excess is also claimed to be responsible for the initiation and progression of the oedema and ischaemia in RVO [9, 10].

The reported patient also presented two other common RVO risk factors, i.e.: dyslipidaemia and obesity. Both conditions are associated with insulin resistance and may further contribute to vessel damage. The discussed pathomechanisms contribute to the development of hypertension at an early age [11].

The other factor which possibly added the risk of the development of the RVO in our patient was

a genetic propensity to hyperhomocysteinaemia. This condition is frequently associated with an enhanced resistive index (derived from carotid ultrasound) as well as with damage to the vascular endothelium [12, 13].

Literature also provides reports on the cases of patients in whom RVO had developed in the course of cancers, thus the RVO may be referred to as a paraneoplastic syndrome. However, in the presented case the diagnosed tumour was least likely to play a key role in the RVO development, as it was at an early stage, unlike in the previous reports [14, 15].

## Conclusions

The aetiology of CRVO in the presented case was multifactorial; however, hypertension was the most probable triggering factor.

## Acknowledgements

The authors have no conflict of interest to disclose.

## Conflict of interest

None declared.

## References

1. Yau JWY, Lee P, Wong TY, et al. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. *Intern Med J*. 2008; 38(12): 904–910, doi: [10.1111/j.1445-5994.2008.01720.x](https://doi.org/10.1111/j.1445-5994.2008.01720.x), indexed in Pubmed: [19120547](https://pubmed.ncbi.nlm.nih.gov/19120547/).
2. Fiebai B, Ejimadu CS, Komolafe RD. Incidence and risk factors for retinal vein occlusion at the University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria. *Niger J Clin Pract*. 2014; 17(4): 462–466, doi: [10.4103/1119-3077.134040](https://doi.org/10.4103/1119-3077.134040), indexed in Pubmed: [24909470](https://pubmed.ncbi.nlm.nih.gov/24909470/).
3. Kida T. Mystery of retinal vein occlusion: vasoactivity of the vein and possible involvement of endothelin-1. *Biomed Res Int*. 2017; 2017: 4816527, doi: [10.1155/2017/4816527](https://doi.org/10.1155/2017/4816527), indexed in Pubmed: [28904960](https://pubmed.ncbi.nlm.nih.gov/28904960/).
4. Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. *Arch Ophthalmol*. 2008; 126(4): 513–518, doi: [10.1001/archophth.126.4.513](https://doi.org/10.1001/archophth.126.4.513), indexed in Pubmed: [18413521](https://pubmed.ncbi.nlm.nih.gov/18413521/).
5. Balogh Z, Berta A, Pfliegler G, et al. Bilateral central retinal vein occlusion caused by malignant hypertension in a young patient. *Clin Exp Hypertens*. 2011; 33(1): 53–55, doi: [10.3109/10641963.2010.503304](https://doi.org/10.3109/10641963.2010.503304), indexed in Pubmed: [21166599](https://pubmed.ncbi.nlm.nih.gov/21166599/).
6. Ponto KA, Elbaz H, Peto T, et al. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. *J Thromb Haemost*. 2015; 13(7): 1254–1263, doi: [10.1111/jth.12982](https://doi.org/10.1111/jth.12982), indexed in Pubmed: [25894549](https://pubmed.ncbi.nlm.nih.gov/25894549/).
7. Giannaki K, Politou M, Rouvas A, et al. Retinal vein occlusion: genetic predisposition and systemic risk factors. *Blood Coagul Fibrinolysis*. 2013; 24(3): 279–283, doi: [10.1097/MBC.0b013e32835b5bfa1](https://doi.org/10.1097/MBC.0b013e32835b5bfa1), indexed in Pubmed: [23337712](https://pubmed.ncbi.nlm.nih.gov/23337712/).
8. Sivaprasad S, Amoaku WM, Hykin P, et al. RVO Guideline Group. The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. *Eye (Lond)*. 2015; 29(12): 1633–1638, doi: [10.1038/eye.2015.164](https://doi.org/10.1038/eye.2015.164), indexed in Pubmed: [26315705](https://pubmed.ncbi.nlm.nih.gov/26315705/).
9. Noma H, Funatsu H, Sakata K, et al. Macular microcirculation in hypertensive patients with and without branch retinal vein occlusion. *Acta Ophthalmol*. 2009; 87(6): 638–642, doi: [10.1111/j.1755-3768.2008.01318.x](https://doi.org/10.1111/j.1755-3768.2008.01318.x), indexed in Pubmed: [18631327](https://pubmed.ncbi.nlm.nih.gov/18631327/).
10. Keilani C, Halalchi A, Wakpi Djeugue D, et al. Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia. *J Fr Ophtalmol*. 2016; 39(10): 816–821, doi: [10.1016/j.jfo.2016.08.007](https://doi.org/10.1016/j.jfo.2016.08.007), indexed in Pubmed: [27865689](https://pubmed.ncbi.nlm.nih.gov/27865689/).
11. Menezes VP, Cohen C, Del-Rei J, et al. Evaluation of endothelial function
12. and arterial stiffness in obese individuals with insulin resistance. *Nutr Health*. 2019 [Epub ahead of print]: 260106018819374, doi: [10.1177/0260106018819374](https://doi.org/10.1177/0260106018819374), indexed in Pubmed: [30614384](https://pubmed.ncbi.nlm.nih.gov/30614384/).
13. Okura T, Miyoshi KI, Irita J, et al. Hyperhomocysteinemia is one of the risk factors associated with cerebrovascular stiffness in hypertensive patients, especially elderly males. *Sci Rep*. 2014; 4: 5663, doi: [10.1038/srep05663](https://doi.org/10.1038/srep05663), indexed in Pubmed: [25012721](https://pubmed.ncbi.nlm.nih.gov/25012721/).
14. Baszczuk A, Kopczyński Z, Thielemann A. [Endothelial dysfunction in patients with primary hypertension and hyperhomocysteinemia]. *Postepy Hig Med Dosw (Online)*. 2014; 68: 91–100, doi: [10.5604/17322693.1087521](https://doi.org/10.5604/17322693.1087521), indexed in Pubmed: [24491900](https://pubmed.ncbi.nlm.nih.gov/24491900/).
15. Adrean SD, Schwab IR. Central retinal vein occlusion and renal cell carcinoma. *Am J Ophthalmol*. 2003; 136(6): 1185–1186, indexed in Pubmed: [14644245](https://pubmed.ncbi.nlm.nih.gov/14644245/).
16. Tonderska M, Ciszewska J, Dróbecka-Brydak E. [Central retinal vein occlusion in the tumor of colon and kidney — difficulties in diagnosis]. *Klin Oczna*. 2005; 107(10–12): 700–702, indexed in Pubmed: [16619824](https://pubmed.ncbi.nlm.nih.gov/16619824/).